Olema posted a higher net loss in Q3 2025 primarily due to greater R&D spending related to the progression of its clinical programs, including palazestrant and OP-3136.

Olema Oncology reported a net loss of $30.4 million for the first quarter of 2025, a slight improvement from the $31.0 million loss in the same period last year, primarily due to higher interest income. The company ended the quarter with $392.7 million in cash, cash equivalents, and marketable securities, indicating a strong financial position to support its ongoing clinical development programs, including the pivotal Phase 3 OPERA-02 and OPERA-01 trials for palazestrant.

Olema Oncology reported a net loss of $33.6 million for the fourth quarter of 2024, an increase from $26.8 million in the same period last year. The company ended the year with $434.1 million in cash, cash equivalents, and marketable securities.

Olema Oncology reported a net loss of $34.6 million for the third quarter of 2024, with cash, cash equivalents, and marketable securities totaling $214.8 million as of September 30, 2024. The company is advancing its clinical programs for palazestrant and OP-3136, with key milestones expected in the near term.

Olema Oncology reported a net loss of $30.4 million for the second quarter of 2024. The company's cash, cash equivalents and marketable securities totaled $239.1 million as of June 30, 2024. Increased spending on clinical development and research activities related to palazestrant and the KAT6 inhibitor program contributed to the increased net loss.

Olema Oncology reported a net loss of $31.0 million for Q1 2024. The company's cash, cash equivalents, and marketable securities totaled $249.0 million as of March 31, 2024. Enrollment was completed in Phase 1b/2 clinical studies of palazestrant in combination with ribociclib and palbociclib, and an IND application for OP-3136 is expected to be filed in late 2024.

Olema Oncology reported a net loss of $26.8 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $261.8 million as of December 31, 2023. They presented clinical results for palazestrant and initiated the OPERA-01 pivotal Phase 3 monotherapy trial.

Olema Pharmaceuticals Inc. reported a net loss of $63.5 million for the third quarter of 2023. The company is focused on the development of its lead product candidate, palazestrant, and continues to advance its clinical programs.

Olema Oncology reported a net loss of $20.1 million for the second quarter ended June 30, 2023, compared to a net loss of $32.9 million for the same period of the prior year. Cash, cash equivalents and marketable securities were $167.4 million as of June 30, 2023, expected to fund operations into the second quarter of 2025.

Olema Oncology reported a net loss of $28.3 million for the first quarter of 2023. As of March 31, 2023, cash, cash equivalents and marketable securities totaled $186.0 million, expected to fund operations into 2025.

Olema Oncology reported a net loss of $26.2 million for the fourth quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $204.4 million as of December 31, 2022, which is expected to fund operations into 2025. The company is focusing on the late-stage clinical development of OP-1250.

Olema Oncology reported a net loss of $22.7 million for the third quarter of 2022. As of September 30, 2022, the company's cash, cash equivalents, and marketable securities totaled $222.6 million, expected to fund operations into the second half of 2024. The company is advancing its OP-1250 clinical development program and combination studies.

Olema Oncology reported a net loss of $32.9 million for the quarter ended June 30, 2022. As of June 30, 2022, the company's cash, cash equivalents, and marketable securities totaled $240.7 million, which is expected to fund operations into the second half of 2024. The company received Fast Track designation from the FDA for OP-1250 for ER+/HER2- metastatic breast cancer treatment and is progressing with OP-1250 clinical development.

Olema Oncology reported a net loss of $23.0 million for the first quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities totaled $267.9 million as of March 31, 2022, which is expected to fund operations into 2024.

Olema Oncology reported a net loss of $17.713 million for the third quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $306 million as of September 30, 2021, which is expected to fund operations through the end of 2023. The company is advancing OP-1250 through clinical trials.

Olema Oncology reported a net loss of $16.4 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $318.1 million as of June 30, 2021, expected to fund operations through the end of 2023.

Olema Oncology reported a net loss of $15.3 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $327.0 million as of March 31, 2021, sufficient to fund operations through the end of 2023. OP-1250 continues to advance in dose-escalation stage of Phase 1/2 clinical trial.

Olema Pharmaceuticals reported a net loss of $10.1 million for the fourth quarter ended December 31, 2020, compared to a net loss of $1.0 million for the fourth quarter ended December 31, 2019. Cash and cash equivalents as of December 31, 2020 were $338.5 million.